Scott Schoenhaus

Keybanc | Healthcare

Scott Schoenhaus is an analyst from Keybanc specializing in the Healthcare sector. Ranked #1450 out of 4771 analysts, they have issued 30 stock ratings with a success rate of 94.16% and an average return of 18.37%.

Scott Schoenhaus has a well-established track record, with 30 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 94.16% and an average return of 18.37%, underscoring their expertise and ability to identify winning opportunities for investors.

#1450

Out of 4771

30

Total Ratings

+94.16%

Success Rate

+18.37%

Average Return

Recent Ratings Analysis

OMCL

Jul 31, 2026

Target

$65.00

Current

$32.25

Performance

-8.82%

Scott Schoenhaus rated OMCL as Overweight on Jul 31, 2026, setting a price target of 65. The stock has underperformed, dropping 8.82% despite the bullish target of 65.

PGNY

Jul 13, 2026

Target

$35.00

Current

$27.08

Performance

-15.32%

On Jul 13, 2026, PGNY was given a Overweight rating by Scott Schoenhaus, with a target price of 35. Despite the Buy call, shares fell from 27.08 to 27.08, challenging the optimistic stance.

HNGE

Jul 13, 2026

Target

$125.00

Current

$88.26

Performance

-1.93%

HNGE received a Overweight rating from Scott Schoenhaus on Jul 13, 2026, aiming for 125. Price action was muted, as shares hovered around 88.26 despite the bullish outlook.

WAY

Jul 02, 2026

Target

$30.00

Current

$23.06

Performance

-1.71%

On Jul 02, 2026, Scott Schoenhaus published a Overweight outlook on WAY, with a target of 30. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 23.06.

ODD

Feb 26, 2026

Target

$50.00

Current

$16.01

Performance

16.27%

Scott Schoenhaus on Feb 26, 2026 assigned ODD a Overweight rating, with a price target of 50. The Buy call aligned well with market performance, producing a gain of 16.27%.

LFST

Feb 26, 2026

Target

$9.00

Current

$13.00

Performance

86.78%

On Feb 26, 2026, Scott Schoenhaus reaffirmed LFST with a Overweight rating, targeting 9. The recommendation was supported by strong follow-through as the stock rose from 13 to 13.

ALIT

Feb 19, 2026

Target

—

Current

$12.05

Performance

-96.28%

ALIT was rated Sector Weight by Scott Schoenhaus on Feb 19, 2026, with a price objective of null. Investors who stayed cautious avoided some of the 96.28% decline.

CERT

Jan 08, 2026

Target

$13.00

Current

$7.42

Performance

-23.27%

On Jan 08, 2026, Scott Schoenhaus initiated coverage on CERT with a Overweight rating and target of 13. The Buy call has yet to be validated as shares remain 5.58 away from the target.

DOCS

Jan 08, 2026

Target

$75.00

Current

$24.71

Performance

-43.51%

Scott Schoenhaus issued a Overweight recommendation for DOCS on Jan 08, 2026, price target set at 75. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

HQY

Jan 08, 2026

Target

$125.00

Current

$94.55

Performance

-4.02%

On Jan 08, 2026, HQY was evaluated by Scott Schoenhaus, who gave a Overweight rating and target of 125. So far, the Buy call awaits clearer momentum, with shares flat at 94.55.

SDGR

Jan 08, 2026

Target

$28.00

Current

$18.80

Performance

1.02%

Scott Schoenhaus rated SDGR as Overweight on Jan 08, 2026, setting a price target of 28. Shares have remained stable near 18.8, leaving the 28 target still in play.

TALK

Jan 08, 2026

Target

$5.00

Current

$5.25

Performance

29.95%

On Jan 08, 2026, TALK was given a Overweight rating by Scott Schoenhaus, with a target price of 5. The stock rallied 29.95% after the rating, narrowing the gap to the target of 5 and validating the bullish stance.

VEEV

Dec 12, 2025

Target

—

Current

$260.98

Performance

16.90%

VEEV received a Sector Weight rating from Scott Schoenhaus on Dec 12, 2025, aiming for null. Investors saw gains of 16.90% that the cautious stance didn’t fully capture.

THC

Oct 08, 2025

Target

$225.00

Current

$263.46

Performance

31.41%

On Oct 08, 2025, Scott Schoenhaus published a Overweight outlook on THC, with a target of 225. Shares gained 31.41%, underscoring the accuracy of the bullish outlook toward 225.

PHR

Oct 08, 2025

Target

$32.00

Current

$10.17

Performance

-56.26%

Scott Schoenhaus on Oct 08, 2025 assigned PHR a Overweight rating, with a price target of 32. The call has struggled to gain traction, with shares losing 56.26%.

HCAT

Oct 08, 2025

Target

$4.00

Current

$1.73

Performance

-39.30%

On Oct 08, 2025, Scott Schoenhaus reaffirmed HCAT with a Overweight rating, targeting 4. Shares slid 39.30% despite the recommendation, highlighting downside risks.

LFMD

Aug 06, 2025

Target

$12.00

Current

$3.03

Performance

-53.60%

LFMD was rated Overweight by Scott Schoenhaus on Aug 06, 2025, with a price objective of 12. This case shows how bullish projections can fail, with the stock now below 3.03.

SLP

Jul 15, 2025

Target

—

Current

$18.42

Performance

42.02%

On Jul 15, 2025, Scott Schoenhaus initiated coverage on SLP with a Sector Weight rating and target of null. The Hold stance underestimated the stock’s strength as it gained 42.02%.

EMN

Jul 14, 2025

Target

$93.00

Current

$68.38

Performance

-13.38%

Scott Schoenhaus issued a Overweight recommendation for EMN on Jul 14, 2025, price target set at 93. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

ABCL

Jul 14, 2025

Target

$10.00

Current

$10.46

Performance

146.70%

On Jul 14, 2025, ABCL was evaluated by Scott Schoenhaus, who gave a Overweight rating and target of 10. This case illustrates how a timely bullish rating can translate into tangible gains of 146.70%.

ALB

Jul 14, 2025

Target

$87.00

Current

$122.11

Performance

69.90%

Scott Schoenhaus rated ALB as Overweight on Jul 14, 2025, setting a price target of 87. The call has proven timely, with shares rising 69.90% toward the price target of 87.

RXRX

Jan 08, 2025

Target

$10.00

Current

$3.16

Performance

-56.47%

On Jan 08, 2025, RXRX was given a Overweight rating by Scott Schoenhaus, with a target price of 10. Despite the Buy call, shares fell from 3.16 to 3.16, challenging the optimistic stance.

GDRX

Jan 08, 2025

Target

$6.00

Current

$3.35

Performance

-21.73%

GDRX received a Overweight rating from Scott Schoenhaus on Jan 08, 2025, aiming for 6. The rating hasn’t played out as hoped, with the stock trading 21.73% below expectations.

ABSI

Jan 08, 2025

Target

$5.00

Current

$8.24

Performance

155.90%

On Jan 08, 2025, Scott Schoenhaus published a Overweight outlook on ABSI, with a target of 5. Shares gained 155.90%, underscoring the accuracy of the bullish outlook toward 5.

Frequency Asked Questions

Who is Scott Schoenhaus?

Scott Schoenhaus is an analyst from Keybanc specializing in the Healthcare sector.

What is Scott Schoenhaus's success rate?

Scott Schoenhaus currently has a success rate of +94.16%.

How many ratings has Scott Schoenhaus issued?

Scott Schoenhaus has issued 30 stock ratings so far.

What is the average return of Scott Schoenhaus's calls?

Their stock ratings have generated an average return of +18.37%.

What is Scott Schoenhaus's ranking?

Scott Schoenhaus is ranked #1450 out of 4771 analysts.

What types of ratings does Scott Schoenhaus give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Scott Schoenhaus?

You can follow Scott Schoenhaus by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Scott Schoenhaus?

Their latest rating was a Buy on OMCL issued on 2026-07-31.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep